Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.
ALX Oncology won fast-track designation from the FDA for its drug ALX148 in the second-line treatment of patients with HER2-positive gastric cancer.
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.